Inclusion Criteria:

          1. Men 18 years or older.

          2. Men who have chosen Active Surveillance as the treatment for their prostate cancer.

          3. Patients who have had a multiparametric MRI of the prostate performed and have
             undergone transrectal systematic biopsy plus biopsy of any lesions (or "areas")
             considered suspicious per the MRI (PIRADS version 2 score of 4 or 5) within 6 months
             before signing consent.

          4. Unilateral Grade Group 2 (Gleason grade 3+4=7) prostate cancer with a total length of
             Gleason pattern 4 no more than 2mm when measured in all systematic biopsy cores plus
             up to 1 core from each targeted biopsy lesion (if more than 1 core is taken from a
             given lesion the core with the longest length of pattern 4 will be included). Note:
             the presence and length of Grade Group 1 (Gleason score 3+3=6) cancer in the biopsy
             will not be considered when determining eligibility.

          5. Prostate cancer clinical stage up to cT2a, N0/Nx, M0/Mx.

          6. Prostate volume ≥20 mL and ≤80 mL

          7. Serum PSA ≤10 ng/mL.

          8. Patients with cT2a and PSA between 10 and 20 ng/mL will have appropriate imaging and
             work up to sufficiently exclude clinical evidence of bone metastases (e.g., bone scan,
             whole body MRI, PET scan, or equivalent). Patients with sites considered "suspicious"
             may be evaluated with confirmatory biopsy to determine eligibility. Patients with
             sites considered "definite" or "consistent with" bone metastases will be excluded.

          9. Men who are sexually active with women of childbearing potential must use
             contraceptive method with a failure rate of less than 1% per year. Contraception
             should be continued for a period of 90 days after the VTP procedure. The individual
             methods of contraception may be determined in consultation with the investigator.

         10. Signed Informed Consent Form.

        Exclusion Criteria:

          1. Grade Group 3, 4 or 5 (≥ Gleason Score 4+3=7) cancer

          2. In patients with Grade Group 2 cancers, a total length of Gleason pattern 4 more than
             2mm when measured in all systematic biopsy cores plus up to 1 core from each targeted
             biopsy lesion (if more than 1 core is taken from a given lesion, include the mm of
             pattern 4 in the 1 core with the longest length of pattern 4)

          3. Bilateral GG 2 cancer

          4. MRI evidence of extracapsular extension of cancer (MRI read as "definite", "frank" or
             "gross" ECE, or MRI lesion with >10mm capsular contact, in an area with biopsy proven
             cancer).

          5. Seminal vesicle invasion on DRE or MRI ("probable" or "consistent with")

          6. Radiographically suspicious lymph node involvement confirmed with biopsy or PET scan.

          7. Any prior or current treatment for prostate cancer, including but not limited to
             surgery, radiation therapy (external or brachytherapy) or chemotherapy;

          8. Life expectancy less than 10 years;

          9. Participation in another clinical study involving an investigational product that in
             the opinion of the investigator may interfere with the endpoints or investigational
             criteria of this study;

         10. Inability to understand the informed consent document, to give consent voluntarily or
             to complete the study tasks, especially inability to understand and fulfill the
             health-related QOL questionnaire;

         11. Any history of a definitively ablative procedure for benign prostatic disease, such as
             benign prostatic hyperplasia, including TURP, whether electrosurgical or thermal laser
             ablation; or high intensity frequency ultrasound (HIFU) or cryotherapy, for focal or
             total ablative therapy of the prostate.

         12. Any condition or history of illness or surgery that may pose an additional risk to men
             undergoing the VTP procedure such as:

               1. Medical conditions that preclude the use of general anesthesia;

               2. Any condition or history of active rectal inflammatory bowel disease or other
                  factors which might increase the risk of fistula formation;

               3. Hormonal manipulation (excluding 5-alpha-reductase inhibitors) that alters
                  androgen production within the previous 6 months;

               4. Oral anticoagulant drugs that could not be withdrawn at least 5 days prior to the
                  VTP procedure or antiplatelet drugs (e.g. aspirin) that could not be withdrawn at
                  least 5 days prior to the VTP procedure and for at least 3 days after VTP;

               5. Renal and hepatic disorders with values of >1.5 times the upper limit of normal
                  (ULN) or blood disorders (upon clinician judgment);

               6. A history of sun hypersensitivity or photosensitive dermatitis.

               7. Any other condition or history of illness or surgery that in the opinion of the
                  investigator might affect the conduct and results of the study or pose additional
                  risks to the patient (e.g., cardiac or respiratory disease precluding general
                  anesthesia, active urethral stricture disease).